Atıf Formatları
Composite CA15-3, LDH, and Albumin Index as a Predictor of Survival in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

N. Kolkıran Et Al. , "Composite CA15-3, LDH, and Albumin Index as a Predictor of Survival in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine," Pharmaceuticals , vol.19, no.6, 2026

Kolkıran, N. Et Al. 2026. Composite CA15-3, LDH, and Albumin Index as a Predictor of Survival in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine. Pharmaceuticals , vol.19, no.6 .

Kolkıran, N., ERDOĞAN, A. P., ŞAHBAZLAR, M., Kurul Yeniay, M., Ünal, S., AKARCA, M. S., ... ATAĞ AKYÜREK, E.(2026). Composite CA15-3, LDH, and Albumin Index as a Predictor of Survival in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine. Pharmaceuticals , vol.19, no.6.

Kolkıran, Nagihan Et Al. "Composite CA15-3, LDH, and Albumin Index as a Predictor of Survival in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine," Pharmaceuticals , vol.19, no.6, 2026

Kolkıran, Nagihan Et Al. "Composite CA15-3, LDH, and Albumin Index as a Predictor of Survival in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine." Pharmaceuticals , vol.19, no.6, 2026

Kolkıran, N. Et Al. (2026) . "Composite CA15-3, LDH, and Albumin Index as a Predictor of Survival in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine." Pharmaceuticals , vol.19, no.6.

@article{article, author={Nagihan Kolkıran Et Al. }, title={Composite CA15-3, LDH, and Albumin Index as a Predictor of Survival in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine}, journal={Pharmaceuticals}, year=2026}